[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
December 23/30, 1998

Bone Mass, Bone Fragility, and the Decision to Treat

Author Affiliations

From Creighton University, Omaha, Neb.

JAMA. 1998;280(24):2119-2120. doi:10.1001/jama.280.24.2119

The explosion of osteoporosis-related diagnostic and therapeutic options in the past 6 to 10 years has created its own challenges. Guidelines have recently been published concerning who should be tested1 but, in a sense, that issue is moot. Bone mass measurement technology is proliferating rapidly, and physicians increasingly are confronted with ostensibly healthy individuals who bring them a printout showing that they have low bone mass. Should the physician recommend one of the growing array of bisphosphonates, selective estrogen receptor modulators, hormone replacement therapy regimens, or dietary supplements? Normally, the clinician treats the patient, not a test, but when it comes to prevention, the test result may be all the physician has to go on.

First Page Preview View Large
First page PDF preview
First page PDF preview
×